$0.92
1.06% yesterday
Nasdaq, Nov 25, 10:18 pm CET
ISIN
US87978U1088
Symbol
TPST
Sector
Industry

Tempest Therapeutics Inc Stock price

$0.92
-0.17 16.05% 1M
-2.33 71.80% 6M
-3.48 79.20% YTD
-2.85 75.73% 1Y
-9.28 91.03% 3Y
-122.98 99.26% 5Y
-5,689.33 99.98% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.01 1.06%
ISIN
US87978U1088
Symbol
TPST
Sector
Industry

Key metrics

Market capitalization $39.94m
Enterprise Value $35.56m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.12
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-35.62m
Free Cash Flow (TTM) Free Cash Flow $-29.49m
Cash position $22.12m
EPS (TTM) EPS $-1.54
P/E forward negative
Short interest 12.62%
Show more

Is Tempest Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Tempest Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Tempest Therapeutics Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Tempest Therapeutics Inc forecast:

Buy
100%

Financial data from Tempest Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.43 0.43
80% 80%
-
-0.43 -0.43
80% 80%
-
- Selling and Administrative Expenses 13 13
78% 78%
-
- Research and Development Expense 22 22
14% 14%
-
-35 -35
24% 24%
-
- Depreciation and Amortization 0.43 0.43
80% 80%
-
EBIT (Operating Income) EBIT -36 -36
16% 16%
-
Net Profit -36 -36
14% 14%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tempest Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tempest Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about 15 hours ago
BRISBANE, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that members of senior management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 9:00...
Neutral
GlobeNewsWire
14 days ago
BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended September 30, 2024, and provided a corporate update.
Neutral
GlobeNewsWire
about 2 months ago
The company is preparing for the Phase 3 study start in the first quarter of 2025 The company is preparing for the Phase 3 study start in the first quarter of 2025
More Tempest Therapeutics Inc News

Company Profile

Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. It develops small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. The company is headquartered in South San Francisco, CA.

Head office United States
CEO Stephen Brady
Employees 17
Founded 2011
Website www.tempesttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today